Mycograb + placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cryptococcal Meningitis
Conditions
Cryptococcal Meningitis
Trial Timeline
Mar 1, 2007 → Sep 1, 2007
NCT ID
NCT00324025About Mycograb + placebo
Mycograb + placebo is a phase 2 stage product being developed by Novartis for Cryptococcal Meningitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00324025. Target conditions include Cryptococcal Meningitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00324025 | Phase 2 | Terminated |
Competing Products
18 competing products in Cryptococcal Meningitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine | Novartis | Phase 2 | 52 |
| Single dose liposomal Amphotericin and Fluconazole + Fluconazole | Gilead Sciences | Phase 2/3 | 64 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Phase 3 | 76 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Lobradimil + Amphotericin B | Alkermes | Phase 1 | 30 |
| Flucytosine and fluconazole + Fluconazole | Bausch Health | Phase 2 | 47 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 1/2 | 33 |
| Encochleated Amphotericin B | Matinas Biopharma | Phase 1/2 | 33 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 3 | 69 |